

# **GENOMIC MEDICINE: PHYSICIAN LITERACY IN CARDIOLOGY**

**William A. Zoghbi, MD, FACC  
President, The American College of Cardiology  
and**

**Robert Roberts, MD, MACC  
President and CEO, University of Ottawa Heart Institute**



**AMERICAN  
COLLEGE *of*  
CARDIOLOGY**



# Overview: Four Important Areas

---

- **Diseases of Particular Interest to CV Medicine**
- **ACC – Personalized Medicine Survey**
- **ACC CME and MoC Offerings**
- **Future ACC Directions**



# 1

## Diseases & Conditions of Particular Genetic/Genomic Interest in CV Medicine

---

- Mendelian CV Diseases
  - Hypertrophic Cardiomyopathy
  - Long QT Syndromes
  - Marfan Syndrome
  - Familial Dilated Cardiomyopathy
  - Factor V Leiden
- Complex Genetic Diseases
  - CAD, HTN
  - Atrial fibrillation
- Pharmacogenetics
  - Warfarin metabolism
  - Clopidogrel activation



# The Current Landscape of Personalized Medicine in Cardiology: *Providers and Patients*

**Source:** ACC's CardioSurve panel  
(Oct. 2010 survey of more than 150 cardiovascular professionals)




*Helping Cardiovascular Professionals  
Learn. Advance. Heal.*

# 2

## ACC Personalized Medicine Survey – 2010

### What is Personalized Medicine?



## 2

## ACC Personalized Medicine Survey - 2010

**Percent of Patients Asking Cardiologists about Personalized Medicine****(n=144)**

0% of patients	33%
1% - 5% of patients	37%
6% - 10% of patients	17%
11% - 20% of patients	8%
More than 20% of patients	5%
Mean % of patients	6%



## 2

## ACC Personalized Medicine Survey - 2010


**Percent of Patients that Cardiologists are Using Personalized Medicine****(n=154)**

0% of patients	29%
1% - 5% of patients	41%
6% - 10% of patients	14%
11% - 20% of patients	9%
More than 20% of patients	7%
Mean % of patients	7%



## 2


# Future Use of Personalized Medicine






# 2

## Future Role of Personalized Medicine



# 2

## Challenges to Clinical Implementation of Personalized Medicine



---

# Importance of Genetics in Cardiovascular Medicine: New Discoveries & Realities

---

January 28 2013

Presented by:

Robert Roberts, MD, FRCPC, MACC, FRSM, Professor of Medicine  
President and CEO, University of Ottawa Heart Institute  
Director, Ruddy Canadian Cardiovascular Genetics Centre

Disclosure: Potential conflicts of interest have been resolved

▪ Cumberland Pharmaceuticals ▪ Celera Corporation



AMERICAN  
COLLEGE *of*  
CARDIOLOGY

# Inherited Causes of Sudden Cardiac Death

## CARDIOMYOPATHIES

**Hypertrophic Cardiomyopathy (HCM)**

**Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)**

**Dilated Cardiomyopathy (DCM)**

**Coronary Artery Abnormalities**

## ARRHYTHMIAS

**Long QT Syndrome (LQTS)**

**Short QT Syndrome**

**Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)**

**Brugada Syndrome**

**Wolff-Parkinson-White (WPW) Syndrome**



# Clinical Screening For HCM

## ≥12 years:

- **Family members should undergo physical examination**
- **ECG and echo at 12 to 18 month intervals**

## 18 to 20 years:

- **ECG and Echo every 5 years unless there is a clinical development**
- **Screening of first degree relatives are encouraged**



# Clinical Considerations

- Screening for causes of sudden cardiac death in the young**
- History and physical examination detects less than 1%**
- ECG exhibits abnormalities in over 80% of individuals with HCM, LQTS and WPW**
- High % of false-positives**



# Role of Genetic Testing in Diagnosis of Cardiomyopathies

- **HCM**
- **Fabry's Disease**
- **Amyloidosis**
- **Other metabolic causes of hypertrophy**



# Role of Genetic Testing in Long QT Syndrome

- Long QTS-1 (Potassium Channel KV7.1) 35%
- Long QTS-2 (Potassium Channel KV11.1) 30%
- Long QTS-3 (Sodium Channel SCN5A) 10%

## Therapy

- Long QTS-1      Beta Blockers
- Long QTS-2      } Beta Blocker plus mexiletine,
- Long QTS-3      } flecainide or ranolazine





# Benefits of Genetic Testing

- **Genetic counseling**
- **Diagnostic**
- **Therapeutic implementation**
- **Cost effective**



# Sudden Death in Athletes

- **75% of all deaths in athletes is cardiac related and almost always precipitated by exertion.**
- **Familial hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death below the age of 36 years.**
- **HCM is almost always asymptomatic, thus no warning precedes sudden death.**

**The following professional sporting organizations endorse ECG screening followed by other tests if abnormal**

- **National Football League (NFL)**
- **Major League Baseball (MLB)**
- **National Basketball Association (NBA)**
- **National Hockey League (NHL)**
- **Major League Soccer (MLS)**



AMERICAN  
COLLEGE of  
CARDIOLOGY

# Role of Genetic Testing in Cardiovascular Pharmacogenomics

- **Anticoagulation**
- **Platelet Therapy**



# 9p21: The First Genetic Risk Factor For CAD



9p21

**9p21 genetic risk variant is extremely common with one or two copies occurring in 75% of the population**

Homozygotes carry increased risk of 50% for CAD  
Heterozygotes carry increased risk of 25% for CAD

**9p21 locus risk is independent of known risk factors for CAD, namely: cholesterol, hypertension or diabetes**

**9p21 risk allele is estimated to be present in 4.5 billion people**



AMERICAN  
COLLEGE of  
CARDIOLOGY

McPherson R, et al. Science 2007;316(5830);1488 – 1491

Helgadottir A, et al. Science 2007;316(5846);1491-3

# Genetics Of Coronary Artery Disease and Myocardial Infarction


**50 genetic risk variants for CAD  
of genome-wide significance  
have been identified  
and replicated in  
independent populations**



AMERICAN  
COLLEGE of  
CARDIOLOGY

CARDIoGRAMplusC4D Consortium.  
Nature Genetics: Jan 2013;Vol.45

# Distribution of Genetic Risk Variants Associated with CAD



# Directives for Cardiology

- The time for genetic testing of cardiovascular Mendelian disorders is now.
- Genetic screening is ultimately necessary for comprehensive prevention of Coronary Artery Disease
- Personalized Medicine is in large part dictated by genetic predisposition

**Structured education of Genetics is a prerequisite to enable our cardiologists to be proactive.**




---

# ACC Educational Offerings in Genetics/Genomics

---



AMERICAN  
COLLEGE *of*  
CARDIOLOGY





# 3

## ACC CME and MoC Offerings

- ACCSAP 8 (ACC Self Assessment Program)  
“Cardiovascular Genetics”
  - CME and MOC (maintenance of certification) offering
  - Mendelian CV Diseases
  - Complex Genetic Diseases
  - Pharmacogenetics



# 3

## ACC CME and MoC Offerings

---

- Annual ACC Scientific Sessions

- ACC.11

- 3 sessions on translational research in genetics, pharmacogenetic tailored antiplatelet therapy, and functional genomics in CV disease

- ACC.12

- 7 sessions on personalized medicine, genome sequencing, translational research, genetic testing, gene therapy for heart failure, and the genetics of sudden cardiac death



# 3

## ACC CME and MoC Offerings

---

- Live Programs – Genetic/Genomic Topics
  - 2011
    - “Genetics and genomics”
    - “Careers in Genetics and Proteomics”
  - 2012
    - “Addressing LV Dysfunction by Gene Therapy Upgrading of Metabolism”
    - “Genetics and Arrhythmias”



# New Lifelong Learning & MOC

## ACC CardioSource

OUR NETWORK ▼ Welcome John Smith Log out

**CardioSource**  
American College of Cardiology

Search

My CardioSource | CardioSource Communities

HOME ACC Science & Quality Lifelong Learning & MOC Annual Conferences Advocacy News/Media Practice Management

Full Catalog [View all >](#) **Key Learning Pathways** Choose a learning pathway to focus on a specialty area.

Lifelong Learning & MOC

Certified Education  
Lifelong Learning Portfolio  
Maintenance of Certification  
Other Educational Resources  
Performance Improvement

HOME > Lifelong Learning & MOC

**NEW IN LIFELONG LEARNING & MOC**

**CCT-SAP 2**  
ACCF Self-Assessment Program

Version 2 of the popular self-assessment program is now available.

**CCT-SAP<sup>®</sup> 2** 1 2 3

**My Learning Portfolio Dashboard**

**What's a Learning Portfolio?**  
Learn about the features and benefits of this tool

- My Self-Assessments
- My Performance Improvement
- My Reflective Learning
- My Curriculum

Title	Action
A New ERA: Evidence-based Stroke and Symptom Reduction in Atrial Fibrillation	Start
Keeping PACE: Patient-centered ACS (Acute Coronary Syndrome) Care Education	Resume
Improving the Evidence-based Management of New-Onset Atrial Fibrillation: 70-year-old female reporting episodes of rapid heart rates associated with symptoms of shortness of breath over the past several weeks	Resume
Overcoming Barriers with Thromboembolic Risk Prevention in Atrial Fibrillation: 66-year-old male diagnosed with afib five years ago on chronic anticoagulation therapy with warfarin	Claim CME
Addressing Persistent Symptoms Despite Adequate Rate Control in Atrial Fibrillation: 51-year-old male diagnosed with afib three years ago experiencing very bothersome symptoms despite good rate control on a beta blocker	Claim CME
<a href="#">View All</a>	

My eLearning Products

**My Credits**

CME Credits: 11.50  
Earned in 2010  
Time left to claim: 42 days  
[Edit Settings](#) | [Transcript](#)

MOC Part II: 6 of 100 points  
MOC Part IV: 0 of 20 CQIs  
Time left to claim: 42 days  
MOC Requirements

**Popular in Education**

Recommended | Commented

- 43rd Annual New York Cardiovascular Symposium: Major Topics in Cardiology Today  
Format: Meetings on Demand  
Credits: [CC](#) 1, [CME](#) 5
- EchoSAP 6  
Format: Self-Assessments / SAPs  
Credits: [CME](#) 1
- CardioQuestions: General Cardiology  
Format: Self-Assessments / SAPs  
Credits: [CME](#) 1, [MOC](#) 5

**Upcoming Live Courses**

Sep 23, 2010  
A New ERA: Evidence-based Stroke and Symptom Reduction in Atrial Fibrillation  
Location: Washington, D.C.  
Credits: [CC](#) 1, [CME](#) 5, [MOC](#) 25

Oct 2, 2010  
Convergence of Type 2 Diabetes and Cardiovascular Disease in conjunction with 2nd Annual Orange County Symposium  
Location: Anaheim, CA  
Credits: [CC](#) 1, [CME](#) 5

Oct 7, 2010  
2010 Heart Valve Summit  
Medical Surgical and



Helping Card.  
Learn. Advan

# ACC Digital Strategy


Optimize  
Delivery  
of Knowledge  
& Decision  
Support tools



AMERICAN  
COLLEGE of  
CARDIOLOGY

# Appropriate Use Criteria (AUC)


- SPECT-MPI
- CCT/MRI
- TTE/TEE
- Stress Echocardiography
- Coronary Revascularization: PCI/CABG
- SPECT MPI Update




Imbed Appropriateness of Genetic testing in Disease Entities & Clinical Scenarios?

- Pacemaker/ICD (2013)
- Multimodality (2013)

# Knowledge & Decision Support Tools at the Point of Care



- Migration towards point-of-order
- Embedded clinical decision support
- Tracking/data registry
- Reporting/feedback



# 4

## Future ACC Direction

---

### ACC BoT Basic Science Advisory Task Force

- Dr. Geoffrey Ginsberg (Chair)
- Dr. Thomas Caskey
- Dr. Robert Roberts
- Dr. Christine Siedman
- Dr. Jennifer Hall
- Dr. Pat O’Gara
- Dr. Deepak Srivastava





# Future Goals

- To develop whitepapers on basic and translational science anticipated to affect cardiovascular practice in the next 10 years.
- To recommend goals for training the next generation of cardiologists (in training and early career) as well as at the current practitioner based on the emerging science and technologies that will impact the practice of cardiovascular medicine
- To advise the ACC on scientific questions, research strategy, and partnerships with other organizations.



**“It’s far more important to know  
what person the disease has than  
what disease the person has.”**

*– Hippocrates*



*Helping Cardiovascular Professionals  
Learn. Advance. Heal.*



**Thank You**



AMERICAN  
COLLEGE *of*  
CARDIOLOGY

# Appropriate Use Criteria (AUC)

Define the “when to do” and “how often to do” a test or procedure in the context of scientific evidence, the health care environment, the patient’s profile and a physician’s judgment

